CLINICAL NEWS
“delalisib may be used earlier in
I
treatment, especially in patients
who have comorbidities or who
cannot tolerate chemotherapy.”
—JENNIFER R. BROWN, MD, PhD
granted based on the results of a
multicenter, single arm, open-label trial
involving 123 patients with relapsed indolent non-Hodgkin lymphomas; twicedaily idelalisib 150 mg was associated
with overall response rates of 54 percent
and 58 percent in patients with FL and
SLL, respectively.
The most common adverse reactions
with idelalisib were diarrhea, pyrexia,
fatigue, nausea, cough, pneumonia,
abdominal pain, chills, and rash. Idelalisib
carries a boxed warning alerting patients
and health-care professionals of the following fatal and serious adverse reactions:
hepatotoxicity, severe diarrhea or colitis,
pneumonitis, and intestinal perforation.
So, where does idelalisib fit in the
treatment landscape? Speaker Jennifer
R. Brown, MD, PhD, an investigator on
the phase I study investigating idelalisib
in CLL, noted that physicians should
consider agents’ toxicity profiles when
choosing between approved therapies.
T:7”
Hepatotoxicity
Inform patients of the risk of hepatotoxicity, including hepatic failure and
death, and to report any signs and symptoms associated with this event to
their healthcare provider for evaluation.
Allergic Reactions
Inform patients of the potential for allergic reactions including
hypersensitivity, angioedema, Stevens Johnsons Syndrome, or toxic
epidermal necrolysis if they had such a reaction to THALOMID and report
symptoms associated with these events to their healthcare provider for
evaluation.
Tumor Lysis Syndrome
Inform patients of the potential risk of tumor lysis syndrome and to report
any signs and symptoms associated with this event to their healthcare
provider for evaluation.
Tumor Flare Reaction
Inform patients of the pote